Kornimate/medical-research-clean huggingface dataset:
effectiveness of the treatment of tension-type headache with manual and manipulative therapy

Conditions: Tension-type Headache

Summary: background. tension-type headache (tth) is the most common form of primary headache and it is a real problem for the subjects suffering from it. until now, physiotherapy treatments have included different techniques combined together, without establishing which of them is more effective. objective. the purpose of this study is to know the effectiveness of manipulative and manual therapy treatments, with regard to pain perception and neck mobility in patients with tension-type headache. methods: a double-blind, randomized clinical trial was conducted, with 84 patients diagnosed with tension-type headache, divided into three treatment groups -manual therapy, manipulative therapy, and a combination of both techniques-, and a placebo control group. four treatment sessions were administered during four weeks, with post-treatment assessment, and follow-up at one month. cervical ranges of motion were assessed (crom device), as well as pain perception (mcgill pain questionnaire), and frequency and intensity of headaches (weekly register).


Eligibility criteria:
inclusion criteria: * subjects aged between 18 and 65 years * diagnosis of frequent etth and ctth * having headache episodes on more than 1 day per month * headache episodes lasting from 30 minutes to 7 days * headaches having at least 2 of the following characteristics: * bilateral location of pain * pressing non pulsating quality * mild or moderate intensity * not aggravated by physical activity * sufferers may present photophobia, phonophobia, nausea or vomiting * headache may be associated with pericranial tenderness * suffering from tth for over 3 months * subjects being under pharmacological control exclusion criteria: * patients with infrequent etth, and patients with probable tth in its frequent and infrequent forms. * headache that is aggravated by head movements. * metabolic or musculoskeletal disorders with symptoms similar to headache * previous neck trauma * vertigo, dizziness, arterial hypertension. * joint stiffness, arteriosclerosis or advanced degenerative osteoarthritis * patients with heart devices * patients in process of pharmacological adaptation * excessive emotional tension * neurological disorders * laxity of neck soft tissues * radiological alterations * general hypermobility or hyperlaxity * joint instability * pregnancy

Keywords: tension-type headache, effectiveness, manual therapy
safety study of stemchymal® in acute liver failure

Conditions: Stem Cells; Adult Stem Cells; Acute Liver Failure; Acute-On-Chronic Liver Failure; Steminent

Summary: to investigate the safety of stemchymal® via intravenous (iv) infusion in acute liver failure (alf) and acute on chronic liver failure (aclf) patients.


Eligibility criteria:
inclusion criteria: 1. alf or aclf patients. 2. subjects are between 20 and 70 years of age. 3. meld scores meet 17 ≤ meld ≤ 26. 4. subjects who had completed signing informed consent. exclusion criteria: 1. subjects who had been enrolled in any other cell therapy within six months. 2. females with a positive pregnancy test result. 3. subjects have contraindication for liver transplantation. 4. subjects with psychiatric illnesses. 5. subjects who are diagnosed as active tuberculosis (tb). 6. subjects with immunological disorders (e.g. autoimmune hepatitis) or using immunosuppressive drugs (e.g. steroid for immunosuppression) within six months prior to screening visit. 7. subjects with unstable illnesses or contraindication for this clinical trial according to investigator's judgment.
np-supported multidisciplinary diabetes management during perioperative period

Conditions: Diabetes

Summary: the primary objective of this study is to determine the benefits of interventions from a multidisciplinary diabetes care team involved of diabetes nurse practitioners(dnp) on glucose control, perioperative outcomes and psychosocial outcomes for patients with diabetes mellitus

about 50% of diabetic patients will undergo at least one surgical operation, and nearly 20% of surgical patients have diabetes.compared with non-diabetic patients, diabetic patients face greater risks during the perioperative period. stress factors such as preoperative preparation, anesthesia, surgical trauma, pain, drugs and negative emotions can induce blood glucose fluctuations, which could lead to complications such as hyperglycemia, diabetic ketosis, and hypoglycemia.therefore, perioperative management has become an important part of diabetes management. a multidisciplinary collaborative team led by np can reduce the mortality of patients after inpatient surgery, help patients change their lifestyle, maintain self-management behavior, improve patient experience, and reduce hospitalization costs. this study intends to explore the application effect of np-led multidisciplinary collaborative team in the perioperative comprehensive management of diabetic patients.

Eligibility criteria:
inclusion criteria: * diagnosis meets world health organization (who) (1999) diabetes diagnostic standards * orthopedic assessment requires elective surgery and no surgical contraindications * hba1c≥8.5% or intravenous fasting blood glucose (fbg)\>10mmol/l * informed consent. exclusion criteria: * cognitive and communication disorders; * pregnancy; * participate in other intervention studies.

Keywords: nurse practitioners, multidisciplinary diabetes management, perioperative period
safety study of bay73-4506 in patients with hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of this study is to determine whether bay73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.


Eligibility criteria:
inclusion criteria: * male or female patients aged equal or above 18 years. * bclc stage category a, b or c that cannot benefit from treatments of established efficacy with higher priority such as resection, liver transplantation, local ablation, chemoembolization or systemic sorafenib. * liver function status child-pugh class a. * failure to prior treatment with sorafenib (defined as radiological progression under sorafenib therapy) * local or loco-regional therapy (eg, surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed = 4 weeks before first dose of bay73-4506. * ecog ps of 0 or 1. * adequate bone marrow, liver and renal function exclusion criteria: * prior systemic treatment with molecular targeted agents for hcc, except sorafenib. prior chemotherapy treatment is allowed. * known history or symptomatic metastatic brain or meningeal tumors (head ct or mri at screening to confirm the absence of central nervous system \[cns\] disease if patient has symptoms suggestive or consistent with cns disease). * congestive heart failure nyha\>/= class 2 * unstable angina (angina symptoms at rest, new onset angina within the last 3 months) or myocardial infarction (mi) within the past 6 months before start of study medication. * cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted). * uncontrolled hypertension (systolic blood pressure \> 150 mmhg or diastolic pressure \> 90 mmhg despite optimal medical management). * arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment.

Keywords: hcc safety bay73-4506
effect of tissue flossing on recovery time after intense physical exercise causing delayed onset muscle soreness

Conditions: Health Behavior; Muscle Strain, Lower Leg

Summary: the aim of the study is to assess whether soft tissue flossing therapy will alleviate eccentric muscle-destroying influences. men aged 20-25 will be tested. suddenly taking up activity in untrained people and performing the fatigue protocol is a heavy burden for the body, and its effects may have a negative impact on the body. the assessment of the processes taking place in the body under the influence of this type of physical activity with the use of soft tissue flossing will broaden the scope of knowledge about this therapeutic method and will allow assessing whether it has an impact on accelerating regeneration after intense physical exertion.


Eligibility criteria:
inclusion criteria: * men aged 20-25 * bmi (body mass index) at the level of 20-35 exclusion criteria: • chronic diseases, musculoskeletal injuries, mental disorders, surgery or hospitalization

Keywords: health behavior hamstring flexibility fascial shearing delayed onset muscle soreness muscle disorder treatment blood flow restriction training myotonometer muscle stiffness
vitamin c, vitamin b1 and steroid in sepsis

Conditions: Sepsis, Severe

Summary: a randomized controlled trial to test the synergic modulation effect of vitamin c, thiamine and hydrocortisone in patients with severe sepsis or septic shock.

management of sepsis bases on three components: infection control, haemodynamic stabilization and modulation of the septic response. many clinical trials conducted agents to block the inflammatory cascade, such as corticosteroids, anti-endotoxins antibodies, tumor necrosis factor (tnf) antagonists, interleukin-1-receptor antagonists, and so on, but none has proven effective to date. a safe, effective, ready available therapy is desperately required. thiamine is a key co-factor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase. all the three enzymes are required to complete krebs cycle to prevent from lactate production. previous studies have found thiamine deficiency to be prevalent in septic shock and other critically ill conditions. one pilot study also proved patients with septic shock and baseline thiamine deficiency would have significant lower lactate level at 24 hours after administration of thiamine. hypress (hydrocortisone for prevention of septic shock) study failed to demonstrate an outcome benefit from a hydrocortisone infusion in patients with sepsis. vitamin c is a potent antioxidant that directly scavenges oxygen free radicals, can restores other cellular antioxidants and plays a role in preserving endothelial function and microcirculatory flow as well. though previous studies suggested that hydrocortisone and vitamin c alone have little impact on the clinical outcome of patients with sepsis. vitamin c and hydrocortisone have many overlapping and synergic pathophysiologic effects in sepsis. both drugs are required for the synthesis of catechlamines and increase vasopressor sensitivity. both drugs can down-regulating the production of proinflammatory mediators, increase tight junctions between endothelial and epithelial cells, preserve endothelial function and microcirculatory flow. marik et al published their study in chest (june 2017) resulting the benefits of combination of vitamin b1, vitamin c and hydrocortisone to severe sepsis and septic shock. however, small sample size and some bias due to imbalanced baseline and study method could confound the results. herein, we would like to lead a randomized controlled trial to test the synergic modulation effect of vitamin c, thiamine and hydrocortisone in patients with severe sepsis or septic shock.

Eligibility criteria:
inclusion criteria: * aged equal or over 20 * admitted to micu due to severe sepsis or septic shock exclusion criteria: * patients who are pregnant * known history of vitamin c , vitamin b or hydrocortisone (or other equivalent products) allergy
prospective study of dietary factors, bmi, and risk of asthma in children

Conditions: Asthma

Summary: asthma is a common illness among children in the united states. while there are many known causes of asthma, including tobacco smoke, pollen, dust, or other allergens, the exact cause of asthma in some individuals remains unknown. this study will examine the role that specific dietary factors and body mass index (bmi) play in the development of childhood asthma.

asthma prevalence has steadily increased in the united states since the early 1980s, but the exact cause of this increase remains unknown. it is estimated that at least 8% of americans have asthma. although anti-inflammatory medications have proven effective for decreasing asthma exacerbations, there are few treatment options available to prevent the initial onset of the disease. dietary factors and bmi may play a role in the development of asthma. specifically, individuals who eat foods containing antioxidants (e.g., vitamin c, vitamin e, and carotenoids), n-3 polyunsaturated fatty acids (e.g., fish oils), and vitamin d may have a decreased risk of developing asthma, while individuals with higher bmi ratios may have an increased asthma risk. the purpose of this study is to evaluate the relationship among dietary factors, bmi, and the incidence of asthma among children. this study will enroll children participating in the growing up today study and children of nurses who are participating in the nurses health study ii. researchers will analyze participants' previously completed questionnaires on dietary intake, physical activity, height, weight, and the presence of physician-diagnosed asthma. all participants with physician-diagnosed asthma will receive an additional asthma questionnaire. a small portion of these participants will also have their medical records reviewed by study researchers, and mothers of these children will be asked to complete a questionnaire. additionally, a questionnaire will be sent to and completed by children who do not have asthma and their mothers.

Eligibility criteria:
inclusion criteria: * children of women in the nurses health study ii (nhs2) * participated in the growing up today study exclusion criteria: * none

Keywords: diet body mass index bmi
phase 1, qt/qtc interval study in healthy subjects

Conditions: Cystic Fibrosis

Summary: this study is designed to evaluate the effect of multiple doses of lumacaftor in combination with ivacaftor on cardiac repolarization, as detected by qt/qtc interval corrected for heart rate in healthy subjects.


Eligibility criteria:
inclusion criteria: * subjects must be willing and able to comply with scheduled visits, treatment plan, lifestyle guidelines, laboratory tests, contraceptive guidelines, and other study procedures. * subjects must be healthy, as defined by no clinically relevant abnormalities identified by a detailed medical history, physical examination, including blood pressure and pulse rate measurement, and 12 lead ecg. * subjects must weigh \>50kg exclusion criteria: * abnormal renal function at screening * plasma donation within 7 days before first study drug dose or blood donation of 1 pint (500ml) within 56 days before first study drug dose * positively screen for hepatitis b, hepatitis c, hiv * known hypersensitivity or prior adverse reaction to moxifloxacin or other quinolones * any condition possibly affecting drug absorption (e.g., gastrectomy, or other gastrointestinal tract surgery, except appendectomy or cholecystectomy or polypectomy) or regular use of acid-lowering therapies (h2 blockers, proton pump inhibitors, and antacids). * female subjects who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last study drug dose and female subjects of childbearing potential who are unwilling or unable to follow the contraceptive guidelines from at least 14 days before the first study drug dose. * male subject who has a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last study drug dose; male subjects who are unwilling or unable to follow the contraceptive guidelines
sex and female empowerment

Conditions: Opioid Use Disorder

Summary: this study will develop and initially evaluate sex and female empowerment (safe), an intervention designed to increase acceptance of and adherence to contraceptive practices among opioid-agonist-maintained women of childbearing age. the intervention will be delivered in one of two formats: a face-to-face brief intervention approach or a novel computer-adaptive platform. to the extent that either version of safe is found to be efficacious compared with usual care, it has the potential to reduce the number of unintended pregnancies and consequently decrease the need for and the costs of child protective services.


Eligibility criteria:
inclusion criteria will be: 1. ages 18-40 years old for women; 2. able to provide informed consent; 3. currently enrolled in a opioid-agonist-maintenance program; 4. currently not pregnant (urine testing confirmation); 5. report heterosexual orientation; 6. no tubal ligation or other sterilization; 7. no plans to become pregnant in the next 6 months; and 8. provides verifiable locator information.

Keywords: pregnancy contraceptive methods family planning services
impact of a letter encouraging pneumococcal vaccination on the 1-year vaccination rate in heart failure patients with a primary care physician

Conditions: Chronic Heart Failure

Summary: heart failure affects more than 1.5 million people in france, resulting in over 70,000 deaths and more than 165,000 hospitalizations each year. viral and bacterial infections are frequently associated with episodes of acute heart failure in patients with chronic heart failure (chf). lower respiratory tract infections, such as influenza and pneumococcus, are common causes of hospitalization for decompensated heart failure, leading to increased morbidity and mortality. studies have shown that pneumococcal vaccination can reduce the risks of heart attack or stroke in patients with heart failure. however, despite vaccination recommendations, coverage rates remain low, especially for pneumococcus. in this study, we will evaluate the impact of an incentive letter for pneumococcal vaccination on one-year hospitalization rate in patients with heart failure.


Eligibility criteria:
inclusion criteria: * adult patients over 45 * residing in the occitanie region, france * with heart failure registered as ald * who have declared an attending physician * who have not received a pneumococcal vaccination for more than 24 months (due to the length of time available in the database) exclusion criteria: -none

Keywords: heart failure hospitalization pneumococcal vaccination
congenital uterine anomalies & pregnancy in polycystic ovarian syndrome

Conditions: Mullerian Anomaly of Uterus, Nec

Summary: prospective research in which patients who applied to uutf gynecology and obstetrics art center for the treatment of infertility (inability to conceive despite one year of unprotected sexual intercourse), who will undergo ivf due to pcos and unexplained infertility

as of 01/10/2020, ivf cycles of patients with pcos (n = 105) and unexplained infertility (n = 105) who have applied to bursa uludag university gynecology and obstetrics department, reproductive treatments center, will be included in the study. demographic data of all patients (age, bmi, smoking), presence of hyperandrogenism findings such as systemic diseases, hirsutism, alopecia, fsh, lh, lh/fsh ratio, estradiol levels, pregestational serum amh levels, uterine anomalies detected by transvaginal usg or hysterosalpingography, controlled ovarian hyperstimulation protocols and doses; besides, dhea-s, free testosterone, 17-oh progesterone levels will be recorded in patients diagnosed with pcos. all these data are routine laboratory and imaging parameters of patients who underwent in vitro fertilization in our uyte center. pregnancy results of the patients (biochemical pregnancy, anembryonic pregnancy, abortion, clinical pregnancy, live birth), perinatal results and complications during clinical pregnancy, delivery ways, and newborn apgar scores will be recorded. results will be compared with patients in the control group diagnosed with unexplained infertility.

Eligibility criteria:
inclusion criteria: * being in the age range of 20-40 * need for an assisted reproductive method due to pcos or unexplained infertility exclusion criteria: * \ 40 years * detecting a cause for infertility other than pcos

Keywords: mullerian anomaly, pcos, antimullerian hormone
a phase 3, multicenter, open-label extension study of phenoptin in subjects with pku who have elevated phenylalanine levels

Conditions: Phenylketonurias

Summary: the primary objective of this trial is to evaluate the safety and tolerability of long-term phenoptin treatment in subjects with pku.


Eligibility criteria:
inclusion criteria: * 8 years of age and older * prior successful participation in study pku-003 * willing and able to provide written informed consent or assent and written informed consent (if required) by a parent or legal guardian * for females of child-bearing potential only: negative urine pregnancy test within 24 hours prior to enrollment. women using acceptable birth control measures must agree to continue to use those measures while participating in the study * willing and able to comply with study procedures * willing to continue current diet unchanged while participating in the study exclusion criteria: * perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable * withdrew from, or otherwise did not successfully complete, study pku-003, except for subjects who were removed from the study because their blood phe exceeded the alert level * expected to require any investigational agent or vaccine prior to completion of all scheduled study assessments * pregnant or breastfeeding, or planning pregnancy * concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes) * requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate) * concurrent use of levodopa

Keywords: phenylalanine hydroxylase
post-marketing surveillance of adalimumab in korean hidradenitis suppurativa subjects

Conditions: Hidradenitis Suppurativa (HS)

Summary: the objective of this study is to evaluate the safety profile of adalimumab for hidradenitis suppurativa (hs) participants in normal medical practice.


Eligibility criteria:
inclusion criteria: * participant who are eligible to be treated with adalimumab for hs in accordance with the approved korean label * participant must provide written authorization form to use their personal health data prior to the participating in the study. exclusion criteria: * participant who are contraindications to adalimumab as listed on the approved korean label. * participant who is participating on other clinical trials.

Keywords: adalimumab safety hidradenitis suppurativa korean participants
sdab-based trnt of multiple myeloma: a feasibility study

Conditions: Multiple Myeloma

Summary: this study aims to show that antiidiotypic sdab are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option for mm patients expressing surface paraprotein.


Eligibility criteria:
inclusion criteria: patients will only be included in the study if they meet all of the following criteria: * patients who have given informed consent * patients at least 18 years old * patients scheduled to undergo bone marrow sampling in clinical routine because of a clinically suspected or pathologically confirmed multiple myeloma. exclusion criteria: patients will not be included in the study if one of the following criteria applies: * patients who cannot communicate reliably with the investigator * patients who are unlikely to cooperate with the requirements of the study * patients at increased risk of death from a pre-existing concurrent illness * patients who participated already in part i of this study